Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Accumulated Expenses (2020 - 2024)

Pulse Biosciences has reported Accumulated Expenses over the past 5 years, most recently at $4.1 million for Q4 2024.

  • Quarterly results put Accumulated Expenses at $4.1 million for Q4 2024, up 28.07% from a year ago — trailing twelve months through Dec 2024 was $4.1 million (up 28.07% YoY), and the annual figure for FY2024 was $4.1 million, up 28.07%.
  • Accumulated Expenses for Q4 2024 was $4.1 million at Pulse Biosciences, up from $2.7 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for PLSE hit a ceiling of $4.6 million in Q2 2021 and a floor of $27000.0 in Q3 2021.
  • Median Accumulated Expenses over the past 5 years was $2.2 million (2020), compared with a mean of $1.9 million.
  • Biggest five-year swings in Accumulated Expenses: plummeted 98.81% in 2021 and later surged 6298.0% in 2023.
  • Pulse Biosciences' Accumulated Expenses stood at $2.3 million in 2020, then surged by 67.57% to $3.8 million in 2021, then crashed by 98.69% to $50000.0 in 2022, then surged by 6298.0% to $3.2 million in 2023, then rose by 28.07% to $4.1 million in 2024.
  • The last three reported values for Accumulated Expenses were $4.1 million (Q4 2024), $2.7 million (Q2 2024), and $2.3 million (Q1 2024) per Business Quant data.